Brokerages Anticipate Quest Diagnostics Inc (NYSE:DGX) Will Announce Quarterly Sales of $1.94 Billion

Analysts expect Quest Diagnostics Inc (NYSE:DGX) to post $1.94 billion in sales for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Quest Diagnostics’ earnings, with estimates ranging from $1.94 billion to $1.95 billion. Quest Diagnostics reported sales of $1.89 billion in the same quarter last year, which would suggest a positive year over year growth rate of 2.6%. The business is scheduled to report its next earnings results before the market opens on Tuesday, October 22nd.

On average, analysts expect that Quest Diagnostics will report full year sales of $7.71 billion for the current financial year, with estimates ranging from $7.67 billion to $7.75 billion. For the next financial year, analysts expect that the firm will report sales of $7.92 billion, with estimates ranging from $7.78 billion to $8.02 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Quest Diagnostics.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.73 EPS for the quarter, beating analysts’ consensus estimates of $1.69 by $0.04. Quest Diagnostics had a return on equity of 15.05% and a net margin of 9.64%. The company had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the prior year, the firm earned $1.75 EPS. The company’s quarterly revenue was up 1.8% compared to the same quarter last year.

A number of equities research analysts have recently commented on DGX shares. JPMorgan Chase & Co. increased their price objective on Quest Diagnostics from $100.00 to $111.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Zacks Investment Research upgraded Quest Diagnostics from a “sell” rating to a “hold” rating and set a $111.00 price objective for the company in a research report on Monday, September 30th. Credit Suisse Group increased their price objective on Quest Diagnostics from $99.00 to $105.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Evercore ISI restated a “buy” rating and issued a $108.00 target price on shares of Quest Diagnostics in a report on Thursday, August 8th. Finally, Canaccord Genuity increased their target price on Quest Diagnostics from $108.00 to $112.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company’s stock. Quest Diagnostics presently has a consensus rating of “Hold” and an average price target of $105.06.

Shares of NYSE:DGX traded up $1.11 on Wednesday, reaching $103.25. 449,149 shares of the company traded hands, compared to its average volume of 1,092,542. Quest Diagnostics has a fifty-two week low of $78.95 and a fifty-two week high of $107.97. The company’s 50 day moving average is $104.14 and its 200-day moving average is $99.07. The stock has a market capitalization of $14.11 billion, a PE ratio of 16.36, a P/E/G ratio of 2.18 and a beta of 0.87. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.82 and a quick ratio of 0.77.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.05%. Quest Diagnostics’s payout ratio is currently 33.60%.

In other news, CAO Michael J. Deppe sold 5,000 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $106.00, for a total value of $530,000.00. Following the completion of the sale, the chief accounting officer now owns 28,671 shares in the company, valued at $3,039,126. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.86% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Berman Capital Advisors LLC increased its stake in shares of Quest Diagnostics by 47.7% in the second quarter. Berman Capital Advisors LLC now owns 319 shares of the medical research company’s stock worth $32,000 after acquiring an additional 103 shares during the last quarter. Financial Advantage Inc. increased its position in Quest Diagnostics by 0.3% during the second quarter. Financial Advantage Inc. now owns 30,316 shares of the medical research company’s stock worth $3,086,000 after buying an additional 104 shares during the last quarter. IFG Advisory LLC increased its position in Quest Diagnostics by 2.5% during the second quarter. IFG Advisory LLC now owns 4,233 shares of the medical research company’s stock worth $430,000 after buying an additional 105 shares during the last quarter. SeaCrest Wealth Management LLC increased its position in Quest Diagnostics by 4.5% during the second quarter. SeaCrest Wealth Management LLC now owns 2,520 shares of the medical research company’s stock worth $257,000 after buying an additional 108 shares during the last quarter. Finally, United Capital Financial Advisers LLC increased its position in Quest Diagnostics by 0.5% during the second quarter. United Capital Financial Advisers LLC now owns 21,547 shares of the medical research company’s stock worth $2,194,000 after buying an additional 108 shares during the last quarter. 89.67% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

See Also: Commodities

Get a free copy of the Zacks research report on Quest Diagnostics (DGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.